NAV

Menaquinone 6

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Menaquinone 6
DrugBank Accession Number
DB14936
Background

Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2).

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 580.8821
Monoisotopic: 580.428031036
Chemical Formula
C41H56O2
Synonyms
  • VITAMIN K2
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
OrlistatOrlistat can cause a decrease in the absorption of Menaquinone 6 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
71ANL51TLA
CAS number
84-81-1
InChI Key
PFRQBZFETXBLTP-RCIYGOBDSA-N
InChI
InChI=1S/C41H56O2/c1-30(2)16-11-17-31(3)18-12-19-32(4)20-13-21-33(5)22-14-23-34(6)24-15-25-35(7)28-29-37-36(8)40(42)38-26-9-10-27-39(38)41(37)43/h9-10,16,18,20,22,24,26-28H,11-15,17,19,21,23,25,29H2,1-8H3/b31-18+,32-20+,33-22+,34-24+,35-28+
IUPAC Name
2-[(2E,6E,10E,14E,18E)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione
SMILES
CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O

References

General References
Not Available
ChemSpider
4446660
RxNav
42781
ZINC
ZINC000072131515

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCalcifications, Vascular1
4CompletedTreatmentOsteoporosis1
4RecruitingTreatmentChronic Kidney Disease (CKD)1
4Unknown StatusPreventionCoronary Artery Calcifications / Kidney Diseases1
2CompletedTreatmentCalcifications, Vascular / Complication of Hemodialysis / Systemic and Arterial Stiffness / Vitamin K2 Deficiency1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000266 mg/mLALOGPS
logP9.01ALOGPS
logP11.8Chemaxon
logS-6.3ALOGPS
pKa (Strongest Basic)-7.2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area34.14 Å2Chemaxon
Rotatable Bond Count17Chemaxon
Refractivity193.11 m3·mol-1Chemaxon
Polarizability74.54 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-014i-3497360000-adde98b2acf7c61c7464
GC-MS Spectrum - EI-BGC-MSsplash10-003r-7891050000-fb45abd0445fd13b3287
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-057r-0415790000-10c09a9433d1b5860532
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0200090000-f9a4dbeaa9f3dfe98c67
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-002r-0911560000-e041d6c2d32113133746
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000l-0507950000-9497c3ede43442817e5f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004j-2502940000-07327595724270e226fc
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kr-0409610000-f03139db31b74c8676b2
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-278.0485415
predicted
DarkChem Lite v0.1.0
[M-H]-265.4111415
predicted
DarkChem Lite v0.1.0
[M-H]-248.0348
predicted
DeepCCS 1.0 (2019)
[M+H]+278.8512415
predicted
DarkChem Lite v0.1.0
[M+H]+265.1851415
predicted
DarkChem Lite v0.1.0
[M+H]+250.04282
predicted
DeepCCS 1.0 (2019)
[M+Na]+278.1311415
predicted
DarkChem Lite v0.1.0
[M+Na]+264.9201415
predicted
DarkChem Lite v0.1.0
[M+Na]+255.80836
predicted
DeepCCS 1.0 (2019)

Drug created at May 20, 2019 14:36 / Updated at June 12, 2020 16:53